Univariate prognostic analyses
| . | . | Overall survival . | Freedom from progression . | Freedom from treatment failure . | |||
|---|---|---|---|---|---|---|---|
| Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | ||
| Patient characteristics | |||||||
| Age | ≥ 45 | 3.87 (1.84-8.15) | .0004 | 1.84 (1.00-3.38) | .049 | 2.63 (1.53-4.53) | .0005 |
| Sex | Male | 2.21 (0.94-5.20) | .07 | 1.58 (0.85-2.92) | .15 | 1.61 (0.91-2.88) | .10 |
| Prognostic parameters | |||||||
| ESR | ≥ 30 | 2.44 (0.99-6.03) | .05 | 3.70 (1.65-8.30) | .002 | 3.29 (1.60-6.74) | .001 |
| ESR | ≥ 50 | 2.27 (1.06-4.85) | .035 | 1.95 (1.08-3.53) | .03 | 2.13 (1.22-3.70) | .008 |
| B symptoms | Yes | 3.21 (1.42-7.30) | .005 | 2.24 (1.23-4.08) | .008 | 2.36 (1.35-4.14) | .003 |
| No. of involved nodal areas | ≥ 4 | 1.63 (0.62-4.30) | .32 | 0.88 (0.35-2.22) | .79 | 0.75 (0.30-1.89) | .55 |
| Albumin | < 40 | 2.35 (1.02-5.37) | .04 | 1.63 (0.89-3.00) | .11 | 1.91 (1.07-3.39) | .028 |
| Hemoglobin | < 10.5 | 2.25 (0.96-5.29) | .06 | 1.89 (0.94-3.82) | .07 | 2.22 (1.19-4.15) | .012 |
| Lymphocytes | < 8 | 1.93 (0.82-4.55) | .13 | 1.71 (0.85-3.44) | .13 | 1.61 (0.83-3.13) | 0.16 |
| Leucocytes | ≥ 15 | 1.85 (0.84-4.09) | .13 | 1.58 (0.83-3.01) | .16 | 1.74 (0.97-3.13) | .06 |
| Ann Arbor stage | 3 or 4 | 2.00 (0.94-4.27) | .07 | 1.62 (0.88-2.98) | .12 | 1.57 (0.89-2.78) | .12 |
| Ann Arbor stage | 4 | 2.42 (1.03-5.70) | .042 | 2.73 (1.41-5.28) | .003 | 2.53 (1.35-4.73) | .004 |
| Prognostic scores | |||||||
| IPS | ≥ 2 | 4.51 (1.54-13.2) | .006 | 2.61 (1.31-5.20) | .006 | 3.13 (1.60-6.14) | .0009 |
| IPS | ≥ 3 | 5.42 (2.32-12.7) | .0001 | 2.49 (1.36-4.57) | .003 | 3.00 (1.70-5.29) | .0001 |
| IPS | ≥ 4 | 5.05 (2.24-11.4) | .0001 | 3.00 (1.53-5.86) | .001 | 3.79 (2.08-6.92) | < .0001 |
| IPS | ≥ 5 | 3.87 (1.84-8.15) | .0004 | 1.84 (1.00-3.38) | .049 | 2.63 (1.53-4.53) | .0005 |
| . | . | Overall survival . | Freedom from progression . | Freedom from treatment failure . | |||
|---|---|---|---|---|---|---|---|
| Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | Relative risk (95% CI) . | P . | ||
| Patient characteristics | |||||||
| Age | ≥ 45 | 3.87 (1.84-8.15) | .0004 | 1.84 (1.00-3.38) | .049 | 2.63 (1.53-4.53) | .0005 |
| Sex | Male | 2.21 (0.94-5.20) | .07 | 1.58 (0.85-2.92) | .15 | 1.61 (0.91-2.88) | .10 |
| Prognostic parameters | |||||||
| ESR | ≥ 30 | 2.44 (0.99-6.03) | .05 | 3.70 (1.65-8.30) | .002 | 3.29 (1.60-6.74) | .001 |
| ESR | ≥ 50 | 2.27 (1.06-4.85) | .035 | 1.95 (1.08-3.53) | .03 | 2.13 (1.22-3.70) | .008 |
| B symptoms | Yes | 3.21 (1.42-7.30) | .005 | 2.24 (1.23-4.08) | .008 | 2.36 (1.35-4.14) | .003 |
| No. of involved nodal areas | ≥ 4 | 1.63 (0.62-4.30) | .32 | 0.88 (0.35-2.22) | .79 | 0.75 (0.30-1.89) | .55 |
| Albumin | < 40 | 2.35 (1.02-5.37) | .04 | 1.63 (0.89-3.00) | .11 | 1.91 (1.07-3.39) | .028 |
| Hemoglobin | < 10.5 | 2.25 (0.96-5.29) | .06 | 1.89 (0.94-3.82) | .07 | 2.22 (1.19-4.15) | .012 |
| Lymphocytes | < 8 | 1.93 (0.82-4.55) | .13 | 1.71 (0.85-3.44) | .13 | 1.61 (0.83-3.13) | 0.16 |
| Leucocytes | ≥ 15 | 1.85 (0.84-4.09) | .13 | 1.58 (0.83-3.01) | .16 | 1.74 (0.97-3.13) | .06 |
| Ann Arbor stage | 3 or 4 | 2.00 (0.94-4.27) | .07 | 1.62 (0.88-2.98) | .12 | 1.57 (0.89-2.78) | .12 |
| Ann Arbor stage | 4 | 2.42 (1.03-5.70) | .042 | 2.73 (1.41-5.28) | .003 | 2.53 (1.35-4.73) | .004 |
| Prognostic scores | |||||||
| IPS | ≥ 2 | 4.51 (1.54-13.2) | .006 | 2.61 (1.31-5.20) | .006 | 3.13 (1.60-6.14) | .0009 |
| IPS | ≥ 3 | 5.42 (2.32-12.7) | .0001 | 2.49 (1.36-4.57) | .003 | 3.00 (1.70-5.29) | .0001 |
| IPS | ≥ 4 | 5.05 (2.24-11.4) | .0001 | 3.00 (1.53-5.86) | .001 | 3.79 (2.08-6.92) | < .0001 |
| IPS | ≥ 5 | 3.87 (1.84-8.15) | .0004 | 1.84 (1.00-3.38) | .049 | 2.63 (1.53-4.53) | .0005 |
Relative risks and their 95% confidence intervals and Ps were estimated for age and gender, for the classical prognostic parameters, and the IPS score. Each line displays the relative risks of patients with the specified characteristic compared to all the other patients.